PMID- 26214631
OWN - NLM
STAT- MEDLINE
DCOM- 20150825
LR  - 20220408
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 20
IP  - 3
DP  - 2015 May-Jun
TI  - An approach of selecting appropriate markers from the primary tumor to enable 
      detection of circulating tumor cells in patients with non-small cell lung cancer.
PG  - 782-90
AB  - PURPOSE: Circulating tumor cells (CTCs) are rare and difficult to isolate, and 
      require selecting minimal but appropriate markers. The aim of this study was to 
      identify markers in the primary non small cell lung cancer (NSCLC) tissue to 
      guide isolation of CTCs from the peripheral blood of patients with lung cancer. 
      METHODS: The expression of CK-19, EGFR and MUC-1 was evaluated by RT-PCR in the 
      NSCLC tumor and paired adjacent normal tissues from 27 patients. The normal 
      cytology, and the neoplastic and fibrotic pathology of the tissue were analyzed 
      by histochemistry. The expression of the markers was analyzed in relation to the 
      stage and grade of disease. RESULTS: Expression analysis showed that 42% of the 
      tumors were positive for CK-19, whereas 85% for both EGFR and MUC-1. Ninety two 
      percent of the tumors expressed any one marker. All (100%) adjacent normal 
      tissues were CK-19 negative, 52% EGFR negative and 44% MUC-1 negative. CK-19 
      expression was specific to the tumor tissue but it was expressed by only 42% of 
      them, manifesting a need for at least three markers to guide the detection of 
      CTCs isolated from the peripheral blood of NSCLC patients. Histopathology 
      demonstrated that 58% were adenocarcinomas, 35% squamous cell carcinomas and 7% 
      had mixed pathology. CONCLUSIONS: This data serves as a prelude and emphasizes 
      the importance of selecting markers expressed in the primary tumor tissue to 
      facilitate and enable enumeration of CTCs.
FAU - Warawdekar, Ujjwala M
AU  - Warawdekar UM
AD  - Mulherkar Laboratory, Advanced Centre for Treatment, Research & Education in 
      Cancer, Tata Memorial Centre, Navi Mumbai, India.
FAU - Sirajuddin, Mohamed M
AU  - Sirajuddin MM
FAU - Pramesh, Conjeevaram S
AU  - Pramesh CS
FAU - Mistry, Rajesh C
AU  - Mistry RC
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Keratin-19)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adenocarcinoma/*blood/chemistry/genetics/pathology
MH  - Adenocarcinoma of Lung
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood/genetics
MH  - Carcinoma, Non-Small-Cell Lung/*blood/chemistry/genetics/pathology
MH  - Carcinoma, Squamous Cell/*blood/chemistry/genetics/pathology
MH  - Cell Line, Tumor
MH  - ErbB Receptors/blood
MH  - Female
MH  - Humans
MH  - Keratin-19/blood
MH  - Lung Neoplasms/*blood/chemistry/genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Mucin-1/blood
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Neoplastic Cells, Circulating/*chemistry
MH  - Predictive Value of Tests
MH  - Real-Time Polymerase Chain Reaction
EDAT- 2015/07/28 06:00
MHDA- 2015/08/26 06:00
CRDT- 2015/07/28 06:00
PHST- 2015/07/28 06:00 [entrez]
PHST- 2015/07/28 06:00 [pubmed]
PHST- 2015/08/26 06:00 [medline]
PST - ppublish
SO  - J BUON. 2015 May-Jun;20(3):782-90.